Encorafenib is an orally available kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in vitro assays. Encorafenib is indicated, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. It is also indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Encorafenib will be discussed in greater detail in subsequent modules.